Last updated on January 2017

A Phase 2/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate Efficacy, Safety and Tolerability of Multiple Dosing Regimens of Oral AGN-241689 in Episodic Migraine Prevention


Brief description of study

A Phase 2/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate Efficacy, Safety and Tolerability of Multiple Dosing Regimens of Oral AGN-241689 in Episodic Migraine Prevention

Detailed Study Description

Receive AGN-241689 or Placebo for the prevention of episodic migraines

Clinical Study Identifier: TX147218

Contact Investigators or Research Sites near you

Start Over

Martha Quinones, CRC

Clinical Research of South Florida
Coral Gables, FL USA
  Connect »

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.